Working…
ClinicalTrials.gov

Key Record Dates

ClinicalTrials.gov Identifier: NCT03924856
Brief Title: Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866) (KEYNOTE-866)

First Submitted : April 22, 2019
First Submitted that Met QC Criteria : April 22, 2019
First Posted : April 23, 2019

Last Update Submitted that Met QC Criteria : February 19, 2021
Last Update Posted : February 21, 2021